Artugen Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
10
- Latest Deal Type
-
M&A
Artugen Therapeutics General Information
Description
Provider of clinical research and development services intended to focus on the development of an antimicrobial agent. The company's services through its antimicrobial agent can kill the Clostridium Difficile bacterium, which is resistant to antibiotics, enabling clients to receive a drug that can act as a preventative treatment against Clostridium Difficile.
Contact Information
Website
www.artugentherapeutics.comCorporate Office
- 530 Virginia Road
- Suite 300
- Concord, MA 01742
- United States
Corporate Office
- 530 Virginia Road
- Suite 300
- Concord, MA 01742
- United States
Artugen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 10-Mar-2022 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series B) | 31-Dec-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series B) | 28-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 28-Jun-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 29-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 30-Nov-2017 | $1.03M | $2.6M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 20-May-2016 | $1.57M | $1.57M | Completed | Clinical Trials - Phase 1 |
Artugen Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Series A | ||||||||
| Series A | 19,511,074 | $0.000100 | $0.04 | $0.04 | 1x | $0.04 | 3.25% | |
| Series A | 1,500,000 | $0.000100 | $0.92 | $0.92 | 1x | $0.92 | 0.25% |
Artugen Therapeutics Signals
Artugen Therapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Morningside Group | Venture Capital | Minority |
Artugen Therapeutics FAQs
-
When was Artugen Therapeutics founded?
Artugen Therapeutics was founded in 2015.
-
Where is Artugen Therapeutics headquartered?
Artugen Therapeutics is headquartered in Concord, MA.
-
What is the size of Artugen Therapeutics?
Artugen Therapeutics has 10 total employees.
-
What industry is Artugen Therapeutics in?
Artugen Therapeutics’s primary industry is Drug Discovery.
-
Is Artugen Therapeutics a private or public company?
Artugen Therapeutics is a Private company.
-
What is Artugen Therapeutics’s current revenue?
The current revenue for Artugen Therapeutics is .
-
How much funding has Artugen Therapeutics raised over time?
Artugen Therapeutics has raised $32.9M.
-
Who are Artugen Therapeutics’s investors?
Morningside Group has invested in Artugen Therapeutics.
-
When was Artugen Therapeutics acquired?
Artugen Therapeutics was acquired on 10-Mar-2022.
-
Who acquired Artugen Therapeutics?
Artugen Therapeutics was acquired by Adiso Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process